SUMMIT, N.J., March 25, 2021 /PRNewswire/ — Seqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) on the company’s cell-based quadrivalent seasonal influenza vaccine (QIVc) in peer-reviewed medical journal Vaccines.1 This retrospective cohort analysis indicated QIVc was more effective in reducing hospitalizations/emergency room (ER) visits caused by influenza, respiratory related hospitalizations/ER visits and all-cause hospitalizations compared with an egg-based quadrivalent influenza vaccine (QIVe) among individuals 4–64 years of age during the 2018/19 U.S. influenza season.1
In an economic analysis, the study also found that QIVc was associated with significantly lower annualized all-cause total costs (($461 savings); p < 0.05) per vaccinated subject, compared with QIVe.1 In the season in which this study was conducted, more than 20 million people in the U.S. received QIVc, indicating a potentially significant public health benefit.2
“Real world studies of influenza vaccines provide critical evidence for understanding the impact of annual immunization linked to the circulating viruses in the community,” said Stephen I. Pelton, MD, Professor of Pediatrics at Boston University School of Medicine and Public Health & Boston Medical Center, and study author. “Current studies demonstrate that QIVc provides significantly higher effectiveness, compared with standard dose egg-based quadrivalent influenza…
